Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-126847 · Präparat HOS-096317
In the neoadjuvant trial NEOSPHERE, in which patients received 4 cycles of Perjeta as neoadjuvant
treatment, the incidence of LVD (during the overall treatment period) was higher in the Perjeta,
trastuzumab and docetaxel-treated group (7.5%) compared to the trastuzumab and docetaxel-treated
group (1.9%). There was one case of symptomatic LVD in the Perjeta and trastuzumab-treated group.
In the neoadjuvant trial TRYPHAENA, the incidence of LVD (during the overall treatment period) was
8.3% in the group treated with Perjeta plus trastuzumab and FEC (5-fluorouracil, epirubicin,
cyclophosphamide) followed by Perjeta plus trastuzumab and docetaxel; 9.3% in the group treated with
Perjeta plus trastuzumab and docetaxel following FEC; and 6.6% in the group treated with Perjeta in
combination with TCH (docetaxel, carboplatin and trastuzumab). The incidence of symptomatic LVD
(congestive heart failure) was 1.3% in the group treated with Perjeta plus trastuzumab and docetaxel
following FEC (this excludes a patient who experienced symptomatic LVD during FEC treatment prior
to receiving Perjeta plus trastuzumab and docetaxel) and also 1.3% in the group treated with Perjeta in
combination with TCH. No patients in the group treated with Perjeta plus trastuzumab and FEC followed
by Perjeta plus trastuzumab and docetaxel experienced symptomatic LVD.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 39ffef9056c5cea33719aa513cf8ecce4074bfae67ad63d6437c2378b159a31b · Zeichen 7199–8670 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10–11
HOS-126848 · Präparat HOS-096317
In the neoadjuvant period of the BERENICE trial, the incidence of NYHA Class III/IV symptomatic
LVD (congestive heart failure according to NCI-CTCAE v.4) was 1.5% in the group treated with dose
dense doxorubicin and cyclophosphamide (AC) followed by Perjeta plus trastuzumab and paclitaxel
and none of the patients (0%) experienced symptomatic LVD in the group treated with FEC followed
10
by Perjeta in combination with trastuzumab and docetaxel. The incidence of asymptomatic LVD
(ejection fraction decrease according to NCI-CTCAE v.4) was 7% in the group treated with dose
dense AC followed by Perjeta plus trastuzumab and paclitaxel and 3.5% in the group treated with FEC
followed by Perjeta plus trastuzumab and docetaxel.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage b76b2ffdb84e26fa0f50655a547603c92c904dbcc51092c05b15411b10fbfda1 · Zeichen 8681–9501 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-126849 · Präparat HOS-096317
In APHINITY, the incidence of symptomatic heart failure (NYHA class III or IV) with a LVEF decline
of at least 10% points from baseline and to <50% was <1% (0.9% of Perjeta-treated patients vs 0.5% of
placebo-treated patients). Of the patients who experienced symptomatic heart failure, 55.6% of Perjeta-
treated patients and 71.4% of placebo-treated patients had recovered (defined as 2 consecutive LVEF
measurements above 50%) at the data cutoff. The majority of the events were reported in anthracycline-
treated patients. Asymptomatic or mildly symptomatic (NYHA class II) declines in LVEF of at least
10% points from baseline and to <50% were reported in 2.9% of Perjeta-treated patients and 3.0% of
placebo-treated patients, of whom 82.4% of Perjeta-treated patients and 83.3% of placebo-treated
patients had recovered at the data cutoff.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 1bb22280260cfeb25a473f4397b5e4a7a828d9acba954817fbdf43e79755ce22 · Zeichen 9503–10347 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-126850 · Präparat HOS-096317
Infusion-related reactions (IRRs)
An infusion-related reaction was defined in the pivotal trials as any event reported as hypersensitivity,
anaphylactic reaction, acute infusion-related reaction or cytokine release syndrome occurring during
an infusion or on the same day as the infusion. In the pivotal trial CLEOPATRA, the initial dose of
Perjeta was given the day before trastuzumab and docetaxel to allow for the examination of Perjeta-
associated reactions. On the first day when only Perjeta was administered, the overall frequency of
infusion-related reactions was 9.8% in the placebo-treated group and 13.2% in the Perjeta-treated
group, with the majority of infusion-related reactions being mild or moderate. The most common
infusion-related reactions (≥ 1.0%) in the Perjeta-treated group were pyrexia, chills, fatigue, headache,
asthenia, hypersensitivity and vomiting.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 1d1b2bc167c27ae2f25ac151eda011bbd18a04fd4a11990b6457a8ca66b8516a · Zeichen 10349–11229 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-126851 · Präparat HOS-096317
During the second cycle when all medicinal products were administered on the same day, the most
common infusion-related reactions in the Perjeta-treated group (≥ 1.0%) were fatigue, dysgeusia, drug
hypersensitivity, myalgia and vomiting (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 4b9b993230945006b6f22b77adc4631196c7e89bc07bbb57c8d023cd504f3edf · Zeichen 11231–11486 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-126852 · Präparat HOS-096317
In neoadjuvant and adjuvant trials, Perjeta was administered on the same day as other study treatments
in all cycles. Infusion-related reactions occurred in 18.6% - 25.0% of patients on the first day of
Perjeta administration (in combination with trastuzumab and chemotherapy). The type and severity of
events were consistent with those observed in CLEOPATRA at the cycles when Perjeta was given on
the same day as trastuzumab and docetaxel, with the majority of reactions being mild or moderate in
severity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage d0045bd9f9e377d1f971e22ef293bf234ea09da03fe57968b638ba57428ba804 · Zeichen 11488–11996 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-126853 · Präparat HOS-096317
Hypersensitivity reactions/anaphylaxis
In the pivotal trial CLEOPATRA in metastatic breast cancer, the overall frequency of investigator
reported hypersensitivity/anaphylaxis events during the entire treatment period was 9.3% in the
placebo-treated group and 11.3% in the Perjeta-treated group, of which 2.5% and 2.0% were
NCI-CTCAE Grade 3-4, respectively. Overall, 2 patients in the placebo-treated group and 4 patients in
the Perjeta-treated group experienced events described as anaphylaxis by the investigator (see section
4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 2cf4e1555cec5e848f59c68f7664c57942c6d6c3bca3f14536615c03ddbcf730 · Zeichen 11998–12531 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-126854 · Präparat HOS-096317
Overall, the majority of hypersensitivity reactions were mild or moderate in severity and resolved
upon treatment. Based on modifications made to the study treatment, most reactions were assessed as
secondary to docetaxel infusions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 9dba4e9ae42ed48ff6ce6cb1426d4785b0196b3d5dcadd6f5ed1bbfc5caa93be · Zeichen 12533–12765 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-126855 · Präparat HOS-096317
In the neoadjuvant and adjuvant trials, hypersensitivity/anaphylaxis events were consistent with those
observed in CLEOPATRA. In NEOSPHERE, two patients in the Perjeta and docetaxel-treated group
experienced anaphylaxis. In both the TRYPHAENA and APHINITY trials, the overall frequency of
hypersensitivity/anaphylaxis was highest in the Perjeta and TCH treated group (13.2% and 7.6%,
respectively), of which 2.6% and 1.3% of events, respectively, were NCI-CTCAE Grade 3-4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 5d7ee57f4ec00c6ed0c1305b7f7264c80f39fd8e0f782cc106a5a7a678d48a2c · Zeichen 12767–13239 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11–12
HOS-126856 · Präparat HOS-096317
11
Febrile neutropenia
In the pivotal trial CLEOPATRA, the majority of patients in both treatment groups experienced at
least one leucopenic event (63.0% of patients in the Perjeta-treated group and 58.3% of patients in the
placebo-treated group), of which the majority were neutropenic events (see section 4.4). Febrile
neutropenia occurred in 13.7% of Perjeta-treated patients and 7.6% of placebo-treated patients. In both
treatment groups, the proportion of patients experiencing febrile neutropenia was highest in the first
cycle of therapy and declined steadily thereafter. An increased incidence of febrile neutropenia was
observed among Asian patients in both treatment groups compared with patients of other races and
from other geographic regions. Among Asian patients, the incidence of febrile neutropenia was higher
in the Perjeta-treated group (25.8%) compared with the placebo-treated group (11.3%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage dab5af27ae57c04d36b4ca6e8b62e444294608a52f1917e7b001ed1a5e04ef0e · Zeichen 13295–14208 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 12
HOS-126857 · Präparat HOS-096317
In the NEOSPHERE trial, 8.4% of patients treated with neoadjuvant Perjeta, trastuzumab and
docetaxel experienced febrile neutropenia compared with 7.5% of patients treated with trastuzumab
and docetaxel. In the TRYPHAENA trial, febrile neutropenia occurred in 17.1% of patients treated
with neoadjuvant Perjeta + TCH, and 9.3% of patients treated with neoadjuvant Perjeta, trastuzumab
and docetaxel following FEC. In TRYPHAENA, the incidence of febrile neutropenia was higher in
patients who received six cycles of Perjeta compared with patients who received three cycles of
Perjeta, independent of the chemotherapy given. As in the CLEOPATRA trial, a higher incidence of
neutropenia and febrile neutropenia was observed among Asian patients compared with other patients
in both neoadjuvant trials. In NEOSPHERE, 8.3% of Asian patients treated with neoadjuvant Perjeta,
trastuzumab and docetaxel experienced febrile neutropenia compared with 4.0% of Asian patients
treated with neoadjuvant trastuzumab and docetaxel.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 53d47302576a7850d25660d6ba1dfb9f86c9f1393c1823cc481e285b5b3f91b6 · Zeichen 14210–15226 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 12
HOS-126858 · Präparat HOS-096317
In the APHINITY trial, febrile neutropenia occurred in 12.1% of Perjeta-treated patients and 11.1% of
placebo-treated patients. As in the CLEOPATRA, TRYPHAENA, and NEOSPHERE trials, a higher
incidence of febrile neutropenia was observed among Perjeta-treated Asian patients compared with
other races in the APHINITY trial (15.9% of Perjeta-treated patients and 9.9% of placebo-treated
patients).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage ee81c0c26454f40b0faf5c44d641d69d8cf4f62b83d74971d55cbf96f6e6b2f5 · Zeichen 15228–15623 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 12
HOS-126859 · Präparat HOS-096317
Diarrhoea
In the pivotal trial CLEOPATRA in metastatic breast cancer, diarrhoea occurred in 68.4% of Perjeta-
treated patients and 48.7% of placebo-treated patients (see section 4.4). Most events were mild to
moderate in severity and occurred in the first few cycles of treatment. The incidence of NCI-CTCAE
Grade 3-4 diarrhoea was 9.3% in Perjeta-treated patients vs 5.1% in placebo-treated patients. The
median duration of the longest episode was 18 days in Perjeta-treated patients and 8 days in placebo-
treated patients. Diarrhoeal events responded well to proactive management with anti-diarrhoeal
agents.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 7ea8d7e5b2d1583a64f8ccb905dcc747c5d4ec12de17b35354a0122c1f544292 · Zeichen 15625–16236 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 12
HOS-126860 · Präparat HOS-096317
In the NEOSPHERE trial, diarrhoea occurred in 45.8% of patients treated with neoadjuvant Perjeta,
trastuzumab and docetaxel compared with 33.6% of patients treated with trastuzumab and docetaxel.
In the TRYPHAENA trial, diarrhoea occurred in 72.3% of patients treated with neoadjuvant
Perjeta+TCH and 61.4% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel
following FEC. In both studies most events were mild to moderate in severity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 4e1b0c0b7024db3869527f6c36defd030c4302701a82ff06fa96b43dd7e03e41 · Zeichen 16238–16694 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 12
HOS-126861 · Präparat HOS-096317
In the APHINITY trial, a higher incidence of diarrhoea was reported in the Perjeta-treated arm
(71.2%) compared to the placebo arm (45.2%). Grade ≥ 3 diarrhoea was reported in 9.8% of patients
in the Perjeta arm vs. 3.7% in the placebo arm. The majority of the reported events were Grade 1 or 2
in severity. The highest incidence of diarrhoea (all Grades) was reported during the targeted
therapy+taxane chemotherapy period (61.4% of patients in the Perjeta arm vs. 33.8% of patients in the
placebo arm).The incidence of diarrhoea was much lower after chemotherapy cessation, affecting
18.1% of patients in the Perjeta arm vs. 9.2% of patients in the placebo arm in the post-chemotherapy
targeted therapy period.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage b10f432aefb86a9fdec4aed0fd642f32431cd683c694feccdc4c3145c7039e96 · Zeichen 16696–17408 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 12
HOS-126862 · Präparat HOS-096317
Rash
In the pivotal trial CLEOPATRA in metastatic breast cancer, rash occurred in 51.7% of Perjeta-treated
patients, compared with 38.9% of placebo-treated patients. Most events were Grade 1 or 2 in severity,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 618841d00180f6f977953e55fba78f959293d0dcc6f12c3744bb142cb351c787 · Zeichen 17410–17618 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 12–13
HOS-126863 · Präparat HOS-096317
12
occurred in the first two cycles, and responded to standard therapies, such as topical or oral treatment
for acne.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 40e3e2ecd86f68b3dc4adc2ac4fed062b847442115e7ab20a46e39cbd1519fde · Zeichen 17670–17788 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 13
HOS-126864 · Präparat HOS-096317
In the NEOSPHERE trial, rash occurred in 40.2% of patients treated with neoadjuvant Perjeta,
trastuzumab and docetaxel compared with 29.0% of patients treated with trastuzumab and docetaxel.
In the TRYPHAENA trial, rash occurred in 36.8% of patients treated with neoadjuvant Perjeta + TCH
and 20.0% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel following FEC.
The incidence of rash was higher in patients who received six cycles of Perjeta compared with patients
who received three cycles of Perjeta, independent of the chemotherapy given.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 91753f6d4838a3a49b309f75042a1933a1db3e7f14fa9ed2b2cb3ef6d8bb8ac2 · Zeichen 17790–18355 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 13
HOS-126865 · Präparat HOS-096317
In the APHINITY trial, the adverse event of rash occurred in 25.8% of patients in Perjeta arm vs.
20.3% of patients in placebo arm. The majority of rash events were Grade 1 or 2.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 45b3a8509f77b222e11b052d00b40bdc778c50c5354c0483ef5ade5c97230bb2 · Zeichen 18357–18535 im Abschnitt
Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 13
HOS-126866 · Präparat HOS-096317
Laboratory abnormalities
In the pivotal trial CLEOPATRA in metastatic breast cancer, the incidence of NCI-CTCAE v.3 Grade
3-4 neutropenia was balanced in the two treatment groups (86.3% of Perjeta-treated patients and
86.6% of placebo-treated patients, including 60.7% and 64.8% Grade 4 neutropenia, respectively).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 45bd29b70dfb0bfdb543b44f35038eaa7951d06d40c630def217fdf7ae3fa84d · Zeichen 18537–18851 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.